Human medicinehttps://www.ema.europa.eu/en/homepageHuman medicineen-gbCopyright: (C) European Medicines AgencyMon, 20 May 2024 17:50:27 +0200Fri, 03 May 2024 16:16:00 +0200Tevimbra : EPAR - Product informationhttps://www.ema.europa.eu/system/files/documents/product-information/ema-combined-h-5919_en_2.pdfTevimbra : EPAR - Product informationhttps://www.ema.europa.eu/system/files/documents/product-information/ema-combined-h-5919_en_2.pdfFri, 03 May 2024 16:16:00 +0200Human medicineHuman medicines European public assessment report (EPAR): Tevimbra, tislelizumab, Date of authorisation: 15/09/2023, Revision: 3, Status: Authorisedhttps://www.ema.europa.eu/en/medicines/human/EPAR/tevimbraHuman medicines European public assessment report (EPAR): Tevimbra, tislelizumab, Date of authorisation: 15/09/2023, Revision: 3, Status: Authorisedhttps://www.ema.europa.eu/en/medicines/human/EPAR/tevimbraFri, 03 May 2024 12:09:00 +0200Human medicine